Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib versus ifosfamide + epirubicin as first-line treatment for metastatic soft tissue sarcoma
ChiCTR1800017424Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib in soft tissue sarcoma (STS) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Progression-free survival. Started Jul 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1800017424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017424.